Medley Pharma up for sale, expected to be sold for Rs 5,000 crore
New Delhi: Medley Pharma, a privately held Mumbai-based pharmaceutical company, is up for sale and is expected to be sold for Rs 5,000 crore in a deal.
According to report in TOI, drug giants Cipla, Dr Reddy's, KKR-backed JB Chemicals, and Torrent, as well as prominent private equity firms Advent, Carlyle, and Blackstone, are all interested in buying the Rs 1,000-crore business.
In addition, as per the sources close to the development, the deal will be worth between Rs 4,000 and Rs 5,000 crore.
According to sources cited by TOI, the promoters are considering a strategic sale of the company's assets, with Cipla being a contender. However, until the press release, the company made no remark.
Medley is a global pharmaceutical company operating since 1969 from Mumbai, India. In the year 1976, a formulation plant with modern facility was set up at Aurangabad followed by units at Daman and Jammu.
Medley Pharmaceuticals Limited is a multidivisional and multi location organization with strong presence in Pharmaceutical formulations. The specialties include Hematinics, Anti ulcerants, Anti bacterials, Pain management, Gynecology & cardiovascular drugs.
According to healthcare market research firm IQVIA, Medley Pharma is among the top 40 pharmaceutical companies in India.
As shown in a recent report from credit rating agency Crisil, the company's revenue for fiscal 2022 is expected to increase by 16 percent to Rs 926 crore from Rs 800 crore the previous year, owing to increased contribution from the acute segment (about 53% of overall sales) and rest from chronic therapies.
Due to logistical issues and the termination of sales to specific African nations such as Uganda and Sudan, where many former payments are still blocked, exports fell to 13 percent of revenue in fiscal 2022, down from 15-18 percent previously.
